Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the company’s forecast came in below estimates, and looming worries about the ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Health and wellness company, which sold alternatives to weight-loss drugs like Wegovy, is now collaborating with Wegovy-maker ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning America" Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

In an abrupt shift Tuesday, the company said it is partnering with Novo Nordisk to make discounted Wegovy available through its platform. After Hims & Hers began selling semaglutide in May 2024 ...

Shares of Hims & Hers Health (NYSE:HIMS) climbed ~36% in the premarket on Tuesday after the telehealth company announced a partnership with Novo Nordisk (NVO) to sell the Danish drugmaker’s popular ...